undamentalytics Newsletter
Sign in

Enanta Pharmaceuticals Inc (ENTA) stock

Add to watchlist

Add holding +

NASDAQ: ENTA Nasdaq Biotechnology Next results ~November 16, 2026

Enanta Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Enanta Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 9 sales by directors and officers, last 12 monthsInsider trades
  • Funds57 adding, 57 cuttingOf 26 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Enanta Pharmaceuticals files

Where Enanta Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $65m, up 0.7% on a year earlier, slower than the 7.4% growth a quarter earlier. Free-cash-flow margin rose to -56.6% from -67.2% a year earlier. Operating margin widened to -90.0% from -149.4%. It passes 2 of our 3 financial-health checks.

Our model value for Enanta Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Enanta Pharmaceuticals Inc's trailing-twelve-month revenue grew 0.7% year on year, with a free-cash-flow margin of -56.6%.

Current signal Net income rising while operating cash flow falls: TTM net income grew 31.3% while operating cash flow fell 52.3% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 59.4 points on a year ago.
  • Shrinking share count. Diluted shares fell 2.9% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 16 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 6.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -90.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -56.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 23.4% of revenue: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 0.9 against the S&P 500.

Latest results: FY2026 Q3

Filed August 12, 2026
Earnings per share
-$0.67 against an average estimate of -$0.54: missed by 25.2%
Revenue
$14m, down 21.6% on a year earlier
Share reaction
-1.8% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 16, 2026; average EPS estimate -$0.77

Enanta Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.6%
  • 1 week-13.1%
  • 1 month-19.5%
  • This year-33.9%
  • 1 year-4.8%
  • 5 years-88.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$65.3M
Operating margin
-90.0%
Net margin
-96.9%

Growth

Revenue growth
+0.7%
Change in growth rate
−6.7 pts

Cash

Free cash flow (TTM)
-$36.9M
FCF margin
-56.6%
Stock pay % of revenue
23.4%

Earnings

Last results
August 10, 2026
Next results (est.)
November 16, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Enanta Pharmaceuticals Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Enanta Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.7 ~$6.9–$26 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Enanta Pharmaceuticals Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025
Share price$26.61$46.80$85.46$60.08$45.78$56.81$51.87$11.17$10.36$11.97
Market value$512m$908m$1.8bn$1.3bn$913m$1.1bn$1.1bn$234m$219m$255m
+ Net debt (− = net cash)−$17m−$66m−$64m−$51m−$87m−$57m−$44m−$85m−$37m−$32m
Enterprise value$495m$843m$1.7bn$1.2bn$826m$1.1bn$1.0bn$149m$182m$223m
Multiples
Price / sales 5.8x8.8x8.5x6.1x7.5x11.8x12.4x3.0x3.2x3.9x
Price / earnings 23.6x51.3x24.5x27.2x——————
Price / free cash flow 16.5x18.1x67.3x19.1x161.8x—————
EV / EBITDA 15.2x31.5x18.7x30.2x——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

17 /100

Weak moat

How hard Enanta Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -19.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -94.2%; its worst year was -170.7%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 3 of 10 years, at a median -61.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, after the close. Analysts expect revenue of $16m and EPS of −$0.77 (range −$0.95 to −$0.55) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.29 +40% $64m −2%
Next −$2.37 −4% $64m −0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +16.8% on 90 days ago. In the last 30 days, 0 analysts raised Enanta Pharmaceuticals Inc's forecast and 2 cut it.

Consensus EPS forecast Enanta Pharmaceuticals Inc, last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.96 Current fiscal year, 60 days ago: −$1.91 Current fiscal year, 30 days ago: −$2.29 Current fiscal year, 7 days ago: −$2.29 Current fiscal year, Now: −$2.29 −$2.29 Next fiscal year, 90 days ago: −$1.98 Next fiscal year, 60 days ago: −$2.07 Next fiscal year, 30 days ago: −$2.37 Next fiscal year, 7 days ago: −$2.37 Next fiscal year, Now: −$2.37 −$2.37

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.96−$1.98
60 days ago −$1.91−$2.07
30 days ago −$2.29−$2.37
7 days ago −$2.29−$2.37
Now −$2.29−$2.37

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.54 −$0.67 −25.2%
Mar 2026 −$0.57 −$0.45 +20.8%
Dec 2025 −$0.80 −$0.42 +47.8%
Sept 2025 −$1.01 −$0.87 +13.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026

No numeric guidance in Enanta Pharmaceuticals Inc's latest earnings release (filed August 10, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026156
  2. Sep 2026156
  3. Aug 2026156
  4. Jul 2026156

Counts of recommendations published by analysts covering Enanta Pharmaceuticals Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.3%
of tradable shares
Days to cover
8.27
at average volume
Short interest, 1 month
−13%
to October 15, 2026
Held by institutions
94%
of shares
Held by insiders
4.7%
of shares
Employees
120
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −4.8%

$10.96 on October 31, 2025 to $10.43

ThenNowEffect
Revenue (last 12 months) $65m $65m +0.7%
P/S multiple 3.6x 4.3x +20.1%
Share count 21m 27m −21.3%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

Last 3 years +11.3%

$9.37 on November 3, 2023 to $10.43

ThenNowEffect
Revenue (last 12 months) $81m $65m −19.0%
P/S multiple 2.4x 4.3x +78.0%
Share count 21m 27m −22.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ENTA+78%−38%−80%−39%+174%−34%
Industry peers (median)−36%−57%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ENTA50%50%25%50%67%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ENTA−29%−50%−85%−67%−50%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 97% from July 9, 2018 to April 10, 2025. Getting back needed a 2866% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$10.43 – $16.85
From 52-week high
−38.1%
vs 50-day average
−16.4%
vs 200-day average
−20.9%
Volatility (1 year)
48%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.7%
After a week
7 up, 5 down
typical move ±13.6%
After a month
6 up, 6 down
typical move ±22.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −1.8% −0.3% −6.8% −3.8%
May 11, 2026 −5.3% +0.1% −12.3% −23.7%
February 9, 2026 +4.6% +0.2% +2.6% +4.9%
November 17, 2025 +2.5% −1.8% +13.2% +18.2%
August 11, 2025 −0.6% +0.9% +18.4% +20.7%
May 12, 2025 −0.8% +4.0% +13.1% +50.9%
February 10, 2025 +14.1% +0.8% +52.9% +48.4%
November 25, 2024 −8.4% +0.9% −6.2% −35.8%
August 5, 2024 −6.5% −2.0% −11.2% −12.7%
May 6, 2024 −13.6% +1.1% −14.9% −18.3%
February 7, 2024 −1.4% +0.9% +5.3% +22.8%
November 20, 2023 +9.2% +0.6% +6.4% −6.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Enanta Pharmaceuticals Inc
$60M $65M $70M $75M $80M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $79.2M Revenue (TTM), FY24 Q1: $73.6M Revenue (TTM), FY24 Q2: $72.9M Revenue (TTM), FY24 Q3: $72M Revenue (TTM), FY24 Q4: $67.6M Revenue (TTM), FY25 Q1: $66.6M Revenue (TTM), FY25 Q2: $64.5M Revenue (TTM), FY25 Q3: $64.8M Revenue (TTM), FY25 Q4: $65.3M Revenue (TTM), FY26 Q1: $67M Revenue (TTM), FY26 Q2: $69.2M Revenue (TTM), FY26 Q3: $65.3M $65.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $79.2M
FY24 Q1 $73.6M
FY24 Q2 $72.9M
FY24 Q3 $72M
FY24 Q4 $67.6M
FY25 Q1 $66.6M
FY25 Q2 $64.5M
FY25 Q3 $64.8M
FY25 Q4 $65.3M
FY26 Q1 $67M
FY26 Q2 $69.2M
FY26 Q3 $65.3M
Revenue growth, TTM YoY Enanta Pharmaceuticals Inc
-20% -10% 0% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -8.1% Revenue growth, TTM YoY, FY24 Q1: -10.3% Revenue growth, TTM YoY, FY24 Q2: -10.2% Revenue growth, TTM YoY, FY24 Q3: -10.7% Revenue growth, TTM YoY, FY24 Q4: -14.6% Revenue growth, TTM YoY, FY25 Q1: -9.6% Revenue growth, TTM YoY, FY25 Q2: -11.6% Revenue growth, TTM YoY, FY25 Q3: -9.9% Revenue growth, TTM YoY, FY25 Q4: -3.4% Revenue growth, TTM YoY, FY26 Q1: 0.6% Revenue growth, TTM YoY, FY26 Q2: 7.4% Revenue growth, TTM YoY, FY26 Q3: 0.7% 0.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -8.1%
FY24 Q1 -10.3%
FY24 Q2 -10.2%
FY24 Q3 -10.7%
FY24 Q4 -14.6%
FY25 Q1 -9.6%
FY25 Q2 -11.6%
FY25 Q3 -9.9%
FY25 Q4 -3.4%
FY26 Q1 0.6%
FY26 Q2 7.4%
FY26 Q3 0.7%
Operating margin (TTM) Enanta Pharmaceuticals Inc
-200% -150% -100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -173.2% Operating margin (TTM), FY24 Q1: -193.0% Operating margin (TTM), FY24 Q2: -185.8% Operating margin (TTM), FY24 Q3: -170.7% Operating margin (TTM), FY24 Q4: -179.9% Operating margin (TTM), FY25 Q1: -165.7% Operating margin (TTM), FY25 Q2: -158.4% Operating margin (TTM), FY25 Q3: -149.4% Operating margin (TTM), FY25 Q4: -130.7% Operating margin (TTM), FY26 Q1: -109.1% Operating margin (TTM), FY26 Q2: -87.2% Operating margin (TTM), FY26 Q3: -90.0% -90.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -173.2%
FY24 Q1 -193.0%
FY24 Q2 -185.8%
FY24 Q3 -170.7%
FY24 Q4 -179.9%
FY25 Q1 -165.7%
FY25 Q2 -158.4%
FY25 Q3 -149.4%
FY25 Q4 -130.7%
FY26 Q1 -109.1%
FY26 Q2 -87.2%
FY26 Q3 -90.0%
FCF margin (TTM) Enanta Pharmaceuticals Inc
-200% -150% -100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -141.7% FCF margin (TTM), FY24 Q1: -134.7% FCF margin (TTM), FY24 Q2: -155.4% FCF margin (TTM), FY24 Q3: -139.4% FCF margin (TTM), FY24 Q4: -143.0% FCF margin (TTM), FY25 Q1: -144.9% FCF margin (TTM), FY25 Q2: -127.6% FCF margin (TTM), FY25 Q3: -67.2% FCF margin (TTM), FY25 Q4: -49.2% FCF margin (TTM), FY26 Q1: -27.6% FCF margin (TTM), FY26 Q2: -13.9% FCF margin (TTM), FY26 Q3: -56.6% -56.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -141.7%
FY24 Q1 -134.7%
FY24 Q2 -155.4%
FY24 Q3 -139.4%
FY24 Q4 -143.0%
FY25 Q1 -144.9%
FY25 Q2 -127.6%
FY25 Q3 -67.2%
FY25 Q4 -49.2%
FY26 Q1 -27.6%
FY26 Q2 -13.9%
FY26 Q3 -56.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Sept 2011 2012 Sept 2012 2013 Sept 2013 2014 Sept 2014 2015 Sept 2015 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 42 42 32 48 161 88 103 207 205 122 97 86 79 68 65 65
EBITDA 26 21 9 19 125 33 27 91 40 −38 −106 −121 −135 −119 −81 −54
Operating income 25 21 9 19 124 31 25 88 37 −42 −110 −124 −137 −122 −85 −59
Net income 23 21 10 34 79 22 18 72 46 −36 −79 −122 −134 −116 −82 −63
Diluted EPS $0.17 $0.14 −$0.34 $1.80 $4.09 $1.13 $0.91 $3.48 $2.21 −$1.81 −$3.92 −$5.91 −$6.38 −$5.48 −$3.84 —
Growth (year on year)
Revenue — −0.4% −23.1% +48.9% +237.0% −45.1% +16.5% +101.0% −0.7% −40.3% −20.7% −11.2% −8.1% −14.6% −3.4% +0.7%
EBITDA — −16.8% −56.9% +109.0% +545.3% −74.0% −17.7% +239.6% −56.0% −195.0% — — — — — —
Operating income — −15.9% −57.6% +110.3% +553.9% −75.2% −20.2% +258.9% −58.4% −213.3% — — — — — —
Net income — −8.2% −55.0% +257.7% +129.4% −72.6% −18.3% +306.3% −35.5% −178.0% — — — — — —
Diluted EPS — −14.4% −337.2% — +127.2% −72.4% −19.5% +282.4% −36.5% −181.9% — — — — — —
Margins
EBITDA margin 61.6% 51.5% 28.9% 40.5% 77.6% 36.8% 26.0% 44.0% 19.5% −31.0% −109.4% −140.3% −170.2% −176.5% −123.6% −82.5%
Operating margin 60.4% 51.0% 28.2% 39.8% 77.2% 34.9% 23.9% 42.7% 17.9% −34.0% −112.9% −143.7% −173.2% −179.9% −130.7% −90.0%
Net margin 55.7% 51.3% 30.0% 72.1% 49.1% 24.5% 17.2% 34.8% 22.6% −29.5% −81.4% −141.3% −169.0% −171.6% −125.4% −96.9%
Free-cash-flow margin 56.3% 53.6% 31.3% 40.1% 46.2% 35.2% 48.8% 12.7% 32.2% 4.6% −72.9% −100.9% −141.7% −143.0% −49.2% −56.6%
Cash flow
Cash from operations 24 23 11 20 77 36 53 29 71 7 −70 −85 −103 −79 −19 −35
Capital spending 0 0 1 1 2 5 3 3 5 1 1 2 9 18 13 2
Free cash flow 24 22 10 19 74 31 50 26 66 6 −71 −87 −112 −97 −32 −37
Stock-based pay 0 0 1 3 6 9 13 16 19 20 21 27 28 27 19 15
Free cash flow after stock pay 23 22 9 16 68 22 37 10 47 −14 −92 −114 −140 −124 −51 −52
Balance sheet
Cash 7 11 9 31 22 17 66 64 51 87 57 44 85 37 32 33
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −7 −11 −9 −31 −22 −17 −66 −64 −51 −87 −57 −44 −85 −37 −32 −33
Diluted shares 15m 20m 20m 19m 19m 19m 19m 21m 21m 20m 20m 21m 21m 21m 21m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $297m
Short-term assets $204mLonger-term assets $93m
What it owes, and who funded it · $297m
Short-term liabilities $54mLonger-term liabilities $142mShareholders' equity $101m
  • Short-term assets cover short-term liabilities $204m of assets due within a year against $54m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $204m short-term assets against $142m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$59m against $13m of interest.

From Enanta Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
132.1%
of revenue
Days sales outstanding
37 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ENTA ABCL CUVL CYTK RXRX WVE Median
Revenue, last 12 months $65m $66m $64m $68m $68m $71m $58m
Revenue growth, last 12 months 0.7% 101.3% 5.2% −21.1% 56.2% 202.3% 12.2%
Revenue growth, 3-year average −6.8% −23.0% — 89.5% 12.9% 20.7% 13.1%
Revenue growth, latest quarter −21.6% −76.3% — −57.1% 258.5% 72.9% 10.2%
Gross margin — — 82.9% — 29.2% — 82.9%
Operating margin −90.0% −340.3% 43.4% <−999% −725.4% −320.9% −187.2%
Operating margin, 3-year average −136.7% −667.5% — <−999% −995.4% −256.4% −361.6%
Net margin −96.9% −248.8% 36.0% <−999% −697.1% −296.9% −163.5%
Cash from operations / revenue −54.1% −143.5% 20.1% −820.8% −455.1% −291.9% −162.3%
Free-cash-flow margin −56.6% −180.8% 18.4% −858.2% −458.0% −293.8% −156.7%
Free-cash-flow margin, 3-year average −87.8% −373.0% — <−999% −664.1% −148.0% −306.5%
Stock pay / revenue 23.4% 77.2% 2.5% 188.1% 129.4% 52.8% 20.7%
Change in share count −2.9% 1.7% 0.7% 4.9% 32.7% 20.2% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to September 30, 2025
Products and services
Line of business Revenue Share YoY
Royalty $65.3M 100.0% ▼ 3.4%
Licenses $0 0.0% —

From Enanta Pharmaceuticals Inc's 10-K filed November 19, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$397M
Institutions reporting
121
Shares held vs prior quarter
▲ 1.8%
Positions opened / closed
11 / 19

Top buyers and sellers, Q2 2026: 57 institutions bought and 57 sold ; the biggest buyer was ADAR1 Capital Management, LLC (+1.3M shares) and the biggest seller Deep Track Capital, LP (−513K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $53.3M 3.7M 13.4% —
Blackrock, Inc. $47.3M 3.2M 11.9% ▲ 4.5%
Krensavage Asset Management, LLC $41.8M 2.9M 10.5% 0.0%
Farallon Capital Management, L.L.C. $35.3M 2.4M 8.9% ▼ 15.8%
Deep Track Capital, LP $21.1M 1.4M 5.3% ▼ 26.2%
ADAR1 Capital Management, LLC $19.6M 1.3M 4.9% ▲ 2518.0%
Vanguard Capital Management LLC $17.7M 1.2M 4.4% ▲ 2.9%
Spruce Street Capital LP $15.9M 1.1M 4.0% ▲ 16.7%
Acadian Asset Management LLC $15.7M 1.1M 4.0% ▲ 22.5%
Vanguard Portfolio Management LLC $14.7M 1.0M 3.7% ▲ 6.6%
Geode Capital Management, LLC $11.3M 777K 2.9% ▲ 7.1%
Millennium Management LLC $9.4M 644K 2.4% ▼ 27.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Enanta Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $183,167 9 trades by 7 insiders · 0% under pre-set plans
Net ▼ $183,167 net selling
Insider Date Trade Shares Price Value
Luly Jay R. President and CEO December 5, 2025 Sell 4,743 $14.23 $67,493
Or Yat Sun Chief Scientific Officer December 5, 2025 Sell 2,390 $14.23 $34,010
Kieffer Tara Lynn Chief Product Strategy Officer December 5, 2025 Sell 2,106 $14.23 $29,968
Luu Brendan Chief Business Officer December 5, 2025 Sell 1,394 $14.23 $19,837
Rottinghaus Scott T. Chief Medical Officer December 5, 2025 Sell 798 $14.23 $11,356
Trout Harry R. Iii See Remarks December 5, 2025 Sell 542 $14.23 $7,713
Capps Kathleen S. See Remarks December 5, 2025 Sell 323 $14.23 $4,596
Trout Harry R. Iii See Remarks December 2, 2025 Sell 380 $13.96 $5,305
Capps Kathleen S. See Remarks December 2, 2025 Sell 207 $13.96 $2,890

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Enanta Pharmaceuticals Inc disclosed in the last 12 months; 3 earlier trades on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded July 12, 2023, filed August 13, 2023
  • Thomas MacArthur(NJ):Sale (full), $1,001 - $15,000, traded May 27, 2015, filed June 7, 2015
  • Thomas MacArthur(NJ):Purchase, $1,001 - $15,000, traded March 20, 2015, filed April 11, 2015

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • February 9, 2026
  • November 17, 2025
  • August 11, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Enanta Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Enanta Pharmaceuticals Inc in brief

What does Enanta Pharmaceuticals Inc do?
Enanta Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in September.
What is Enanta Pharmaceuticals Inc's stock ticker?
Enanta Pharmaceuticals Inc trades under the ticker ENTA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Enanta Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Enanta Pharmaceuticals Inc reported revenue of $65.3M, 0.7% higher than a year earlier, according to its SEC filings.
What is Enanta Pharmaceuticals Inc's free cash flow?
Enanta Pharmaceuticals Inc's free-cash-flow margin is -56.6% of revenue over the trailing twelve months.
Who are Enanta Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Blackrock, Inc. and Krensavage Asset Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Enanta Pharmaceuticals Inc's market cap?
On September 30, 2025, Enanta Pharmaceuticals Inc's market capitalisation was about $255M and net debt of -$32.3M. Market figures come from third-party market data and may be delayed.
Who are Enanta Pharmaceuticals Inc's competitors?
In our Biotechnology peer group, the companies closest to Enanta Pharmaceuticals Inc are Abcellera Biologics Inc., Clinuvel Pharmaceuticals Ltd, Cytokinetics Inc, Recursion Pharmaceuticals, Inc. and Wave Life Sciences, Inc. The side-by-side comparison below sets their revenue, margins and growth against Enanta Pharmaceuticals Inc's.
Are insiders buying or selling Enanta Pharmaceuticals Inc stock?
Over the last 12 months, Enanta Pharmaceuticals Inc's directors and officers reported 0 open-market purchases and 9 sales on Form 4. The insider trading page charts every trade.
When is Enanta Pharmaceuticals Inc's next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Enanta Pharmaceuticals Inc announces its own schedule.